Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Melanoma treatment necessitates novel therapeutic strategies.
• Cardiac glycosides exhibit selective toxicity towards melanoma cells.
• The ATP1A1 Na(+)/K(+) pump is highly expressed in melanoma cells.

Purpose of the Study:

• To investigate the efficacy of cardiac glycosides, specifically digitoxin, as a melanoma therapy.
• To explore the synergistic effects of combining digitoxin with MEK and/or BRAF inhibitors.
• To elucidate the underlying mechanisms of action for combination therapy in melanoma.

Main Methods:

• In vitro toxicity assays on human melanoma cells and normal cells.
• In vivo studies using patient-derived melanomas in NSG mice.
• Analysis of cellular signaling pathways, including ERK phosphorylation.
• Assessment of ion gradients, membrane potentials, and cellular energy levels.

Main Results:

• Digitoxin and digoxin demonstrated significantly higher toxicity to melanoma cells than normal cells.
• Combination therapy with digitoxin and MEK/BRAF inhibitors synergistically inhibited melanoma growth in vivo.
• The combination therapy did not induce cell death in normal human melanocytes or hematopoietic cells.
• Mechanistically, the combination induced intracellular acidification, mitochondrial calcium dysregulation, and ATP depletion in melanoma cells.

Conclusions:

• Cardiac glycosides, particularly digitoxin, represent a promising therapeutic agent for melanoma.
• Combination therapy with targeted inhibitors (MEK/BRAF) and digitoxin shows synergistic potential for melanoma treatment.
• Targeting ion homeostasis in cancer cells can enhance the efficacy of existing targeted therapies, leading to tumor regression.